David Rescot's questions to Nyxoah SA (NYXH) leadership • Q2 2025
Question
David Rescot of Baird sought clarification on the VAC and prior authorization processes, and asked about the timeline for the ACCESS study data and how the company can approach the CCC patient population before and after those results are available.
Answer
CFO John Landry and CEO Olivier Talman explained that the reimbursement process leverages the established AGNS CPT code, with approvals based on demonstrating GENEO's clinical efficacy. Talman reiterated that ACCESS data is expected in 12 months, with a potential label expansion by early 2027. He clarified that while CCC is not contraindicated, it is currently an off-label use in the U.S. and will not be actively promoted until the label is updated.